

# Review of: "Enhancing Patient-Centric Approaches and Regulatory Measures in Valproate Use"

Marta Vázquez

Potential competing interests: No potential competing interests to declare.

While the paper addresses an interesting issue, it is not publishable in its current form. There are main reasons for my comment.

Firstly, the article lacks a proper structure. The nature of this article is not clearly defined. (What type of article is it?)

Secondly, it lacks up-to-date references, and lastly, important information about VPA adverse effects is missing. Just to cite two examples, 1-valproic acid–associated hyperammonemia is a common adverse effect that may occur within the therapeutic range of VPA. Elevated ammonia levels may occur after acute overdoses or with chronic use of VPA and do not necessarily cause encephalopathy. Most cases present asymptotically with normal liver function tests. Supplementation of L-carnitine is postulated to increase the beta-oxidation of VPA, interrupting the mechanism by which it causes hyperammonemia. 2-Thrombocytopenia is one of the prominent side effects of VPA which can cause serious problems. Drug-induced immune thrombocytopenia is a serious clinical problem that is under-recognized, difficult to diagnose, and can cause severe bleeding complications. Recognition of this reaction is important, and clinicians should monitor hematologic labs, including platelets, for patients receiving VPA.

Therefore, there are many things to be improved, and I recommend a thorough revision of the article.